Advances in Public Health / 2022 / Article / Tab 2 / Research Article
Pentazocine Misuse among Sickle Cell Disease Patients and The Role of Lack of Enforcement of Opioid Dispensing Regulations by Community Pharmacies: A Descriptive Observational Study Table 2 Participants’ details on pentazocine abuse.
Frequency Percentage Duration of self-pentazocine use (years) <1 1 4.8 1-2 5 23.8 >2 15 71.4 Frequency of pentazocine use Daily 11 52.3 At least once/week 3 14.2 At least once/month 4 19.0 Only during painful crises 3 14.2 Usual dose per time (milligram) 30–60 mg 2 9.5 90–150 mg 16 76.1 >150 mg 3 14.2 Dose increment with time 20 95.2 First knowledge of self-use Fellow SCD friend taught me 4 19.0 At home by a nearby health worker/parent 9 42.8 During hospital admission for pain crisis 1 4.7 Treatment from pharmacy/chemist shop 7 33.3 Procurement of pentazocine Home delivery 4 19.0 Open market 2 9.5 Chemist/patient medicine shops 3 14.2 Community pharmacy outlets 12 57.1 Requires prescription 2 9.5 Route of administration Intravenous 2 9.5 Intramuscular 19 90.5 Injection sites Buttocks 15 71.4 Thigh 7 33.3 Arm 5 23.8 Reuses/shares needles 4 19.0 Complications of pentazocine use Chronic ulcers 7 33.3 Healed scars 2 9.5 Abscess 9 42.8 Disabilities 2 9.5 Ankylosis 2 9.5 Leg swelling/induration 5 23.8 Sedation 5 23.8